Clarivate (NYSE:CLVT – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.03, FiscalAI reports. Clarivate had a positive return on equity of 9.73% and a negative net margin of 17.02%. The company had revenue of $481.60 million during the quarter, compared to the consensus estimate of $566.77 million. During the same period in the prior year, the company earned $0.18 earnings per share. The company’s revenue for the quarter was down 22.7% compared to the same quarter last year.
Here are the key takeaways from Clarivate’s conference call:
- Recurring growth improved: Organic ACV growth rose to 1.8% and recurring organic revenue growth reached 1.3%, while IP ACV returned to positive growth for the first time in more than three years.
- Clarivate reported strong customer traction for its AI products, including more than 100 institutional wins for Web of Science Research Intelligence and a 151-customer pipeline for the upcoming IPOne platform.
- The completed Life Sciences & Healthcare divestiture leaves Clarivate focused on Academia & Government and IP, with a 93% recurring organic revenue mix; management expects the portfolio simplification and cost controls to support margin expansion.
- The company repurchased approximately $293 million of debt year to date, plans to use divestiture proceeds for additional discounted buybacks, and expects to reduce total debt by about $875 million in 2026.
- Continuing-operations revenue is expected to decline to $1.965 billion-$1.985 billion for 2026, primarily because of strategic disposals, while free cash flow guidance was reduced to $320 million-$340 million after transaction costs and the loss of seasonal Life Sciences & Healthcare cash flow.
Clarivate Stock Performance
CLVT traded up $0.15 on Thursday, reaching $2.27. The company had a trading volume of 4,111,738 shares, compared to its average volume of 6,013,117. Clarivate has a fifty-two week low of $1.42 and a fifty-two week high of $3.87. The stock has a market cap of $1.46 billion, a P/E ratio of -3.66 and a beta of 1.38. The company’s fifty day moving average is $1.81 and its 200 day moving average is $2.21. The company has a debt-to-equity ratio of 0.93, a quick ratio of 0.85 and a current ratio of 0.85.
Analyst Ratings Changes
CLVT has been the subject of a number of recent analyst reports. The Goldman Sachs Group cut their price target on shares of Clarivate from $2.60 to $2.30 and set a “neutral” rating for the company in a research note on Thursday. Morgan Stanley started coverage on shares of Clarivate in a report on Friday, October 30th. They issued an “underweight” rating and a $1.50 target price on the stock. Barclays cut their target price on shares of Clarivate from $2.50 to $2.00 and set an “underweight” rating for the company in a research note on Thursday, July 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Clarivate in a research report on Monday, September 21st. Finally, Stifel Nicolaus dropped their price objective on Clarivate from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. One analyst has rated the stock with a Buy rating, five have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $2.65.
Read Our Latest Research Report on CLVT
Insider Transactions at Clarivate
In other news, Director Kenneth Cornick acquired 250,000 shares of Clarivate stock in a transaction dated Friday, August 7th. The stock was bought at an average price of $1.85 per share, for a total transaction of $462,500.00. Following the completion of the acquisition, the director directly owned 2,000,000 shares in the company, valued at approximately $3,700,000. The trade was a 14.29% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 22.88% of the stock is owned by company insiders.
Clarivate Company Profile
Clarivate Plc (NYSE:CLVT) provides analytics, data, and workflow solutions to organizations in academia, government, research, life sciences, and intellectual property. Its offerings are designed to help customers evaluate research, manage information, accelerate innovation, and support strategic decision-making.
The company’s products include Web of Science research databases and citation analytics, InCites research evaluation tools, Derwent innovation and patent intelligence services, and Cortellis life sciences and drug-development information.
Featured Stories
- Five stocks we like better than Clarivate
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
- South Korea’s Chip Exports Are Soaring—So Why Is This ETF Down 20%?
Receive News & Ratings for Clarivate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarivate and related companies with MarketBeat.com's FREE daily email newsletter.
